Cargando…
Understanding WT1 Alterations and Expression Profiles in Hematological Malignancies
SIMPLE SUMMARY: The transcription factor Wilms tumor one (WT1) is highly expressed in malignant cells of patients with hematological malignancies, with a considerable percentage of patients harboring deactivating mutations in this gene. To date, the extent of WT1’s contribution to leukemogenesis is...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340278/ https://www.ncbi.nlm.nih.gov/pubmed/37444601 http://dx.doi.org/10.3390/cancers15133491 |
_version_ | 1785072040388067328 |
---|---|
author | Niktoreh, Naghmeh Weber, Lisa Walter, Christiane Karimifard, Mahshad Hoffmeister, Lina Marie Breiter, Hannah Thivakaran, Aniththa Soldierer, Maren Drexler, Hans Günther Schaal, Heiner Sendker, Stephanie Reinhardt, Dirk Schneider, Markus Hanenberg, Helmut |
author_facet | Niktoreh, Naghmeh Weber, Lisa Walter, Christiane Karimifard, Mahshad Hoffmeister, Lina Marie Breiter, Hannah Thivakaran, Aniththa Soldierer, Maren Drexler, Hans Günther Schaal, Heiner Sendker, Stephanie Reinhardt, Dirk Schneider, Markus Hanenberg, Helmut |
author_sort | Niktoreh, Naghmeh |
collection | PubMed |
description | SIMPLE SUMMARY: The transcription factor Wilms tumor one (WT1) is highly expressed in malignant cells of patients with hematological malignancies, with a considerable percentage of patients harboring deactivating mutations in this gene. To date, the extent of WT1’s contribution to leukemogenesis is still unclear and this, at least in part, results from the complexity of WT1 regulation and is further complicated by the lack of an appropriate model system to study WT1 isoform formation under settings closer to reality. In the present study, we describe a set of leukemia and lymphoma cell lines, which are carefully characterized for WT1’s unique properties and thoroughly screened for sequence alterations in WT1 and other genes important for leukemogenesis. We studied the formation of endogenous truncated WT1 and developed a model system for the study of WT1 major isoforms, thus significantly contributing to the field of WT1 research. ABSTRACT: WT1 is a true chameleon, both acting as an oncogene and tumor suppressor. As its exact role in leukemogenesis is still ambiguous, research with model systems representing natural conditions surrounding the genetic alterations in WT1 is necessary. In a cohort of 59 leukemia/lymphoma cell lines, we showed aberrant expression for WT1 mRNA, which does not always translate into protein levels. We also analyzed the expression pattern of the four major WT1 protein isoforms in the cell lines and primary AML blasts with/without WT1 mutations and demonstrated that the presence of mutations does not influence these patterns. By introduction of key intronic and exonic sequences of WT1 into a lentiviral expression vector, we developed a unique tool that can stably overexpress the four WT1 isoforms at their naturally occurring tissue-dependent ratio. To develop better cellular model systems for WT1, we sequenced large parts of its gene locus and also other important myeloid risk factor genes and revealed previously unknown alterations. Functionally, inhibition of the nonsense-mediated mRNA decay machinery revealed that under natural conditions, the mutated WT1 alleles go through a robust degradation. These results offer new insights and model systems regarding the characteristics of WT1 in leukemia and lymphoma. |
format | Online Article Text |
id | pubmed-10340278 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103402782023-07-14 Understanding WT1 Alterations and Expression Profiles in Hematological Malignancies Niktoreh, Naghmeh Weber, Lisa Walter, Christiane Karimifard, Mahshad Hoffmeister, Lina Marie Breiter, Hannah Thivakaran, Aniththa Soldierer, Maren Drexler, Hans Günther Schaal, Heiner Sendker, Stephanie Reinhardt, Dirk Schneider, Markus Hanenberg, Helmut Cancers (Basel) Article SIMPLE SUMMARY: The transcription factor Wilms tumor one (WT1) is highly expressed in malignant cells of patients with hematological malignancies, with a considerable percentage of patients harboring deactivating mutations in this gene. To date, the extent of WT1’s contribution to leukemogenesis is still unclear and this, at least in part, results from the complexity of WT1 regulation and is further complicated by the lack of an appropriate model system to study WT1 isoform formation under settings closer to reality. In the present study, we describe a set of leukemia and lymphoma cell lines, which are carefully characterized for WT1’s unique properties and thoroughly screened for sequence alterations in WT1 and other genes important for leukemogenesis. We studied the formation of endogenous truncated WT1 and developed a model system for the study of WT1 major isoforms, thus significantly contributing to the field of WT1 research. ABSTRACT: WT1 is a true chameleon, both acting as an oncogene and tumor suppressor. As its exact role in leukemogenesis is still ambiguous, research with model systems representing natural conditions surrounding the genetic alterations in WT1 is necessary. In a cohort of 59 leukemia/lymphoma cell lines, we showed aberrant expression for WT1 mRNA, which does not always translate into protein levels. We also analyzed the expression pattern of the four major WT1 protein isoforms in the cell lines and primary AML blasts with/without WT1 mutations and demonstrated that the presence of mutations does not influence these patterns. By introduction of key intronic and exonic sequences of WT1 into a lentiviral expression vector, we developed a unique tool that can stably overexpress the four WT1 isoforms at their naturally occurring tissue-dependent ratio. To develop better cellular model systems for WT1, we sequenced large parts of its gene locus and also other important myeloid risk factor genes and revealed previously unknown alterations. Functionally, inhibition of the nonsense-mediated mRNA decay machinery revealed that under natural conditions, the mutated WT1 alleles go through a robust degradation. These results offer new insights and model systems regarding the characteristics of WT1 in leukemia and lymphoma. MDPI 2023-07-04 /pmc/articles/PMC10340278/ /pubmed/37444601 http://dx.doi.org/10.3390/cancers15133491 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Niktoreh, Naghmeh Weber, Lisa Walter, Christiane Karimifard, Mahshad Hoffmeister, Lina Marie Breiter, Hannah Thivakaran, Aniththa Soldierer, Maren Drexler, Hans Günther Schaal, Heiner Sendker, Stephanie Reinhardt, Dirk Schneider, Markus Hanenberg, Helmut Understanding WT1 Alterations and Expression Profiles in Hematological Malignancies |
title | Understanding WT1 Alterations and Expression Profiles in Hematological Malignancies |
title_full | Understanding WT1 Alterations and Expression Profiles in Hematological Malignancies |
title_fullStr | Understanding WT1 Alterations and Expression Profiles in Hematological Malignancies |
title_full_unstemmed | Understanding WT1 Alterations and Expression Profiles in Hematological Malignancies |
title_short | Understanding WT1 Alterations and Expression Profiles in Hematological Malignancies |
title_sort | understanding wt1 alterations and expression profiles in hematological malignancies |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340278/ https://www.ncbi.nlm.nih.gov/pubmed/37444601 http://dx.doi.org/10.3390/cancers15133491 |
work_keys_str_mv | AT niktorehnaghmeh understandingwt1alterationsandexpressionprofilesinhematologicalmalignancies AT weberlisa understandingwt1alterationsandexpressionprofilesinhematologicalmalignancies AT walterchristiane understandingwt1alterationsandexpressionprofilesinhematologicalmalignancies AT karimifardmahshad understandingwt1alterationsandexpressionprofilesinhematologicalmalignancies AT hoffmeisterlinamarie understandingwt1alterationsandexpressionprofilesinhematologicalmalignancies AT breiterhannah understandingwt1alterationsandexpressionprofilesinhematologicalmalignancies AT thivakarananiththa understandingwt1alterationsandexpressionprofilesinhematologicalmalignancies AT soldierermaren understandingwt1alterationsandexpressionprofilesinhematologicalmalignancies AT drexlerhansgunther understandingwt1alterationsandexpressionprofilesinhematologicalmalignancies AT schaalheiner understandingwt1alterationsandexpressionprofilesinhematologicalmalignancies AT sendkerstephanie understandingwt1alterationsandexpressionprofilesinhematologicalmalignancies AT reinhardtdirk understandingwt1alterationsandexpressionprofilesinhematologicalmalignancies AT schneidermarkus understandingwt1alterationsandexpressionprofilesinhematologicalmalignancies AT hanenberghelmut understandingwt1alterationsandexpressionprofilesinhematologicalmalignancies |